Bacterial Interference for Preventing Recurrent Urinary Tract Infection - New Ways of Treatment

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-90
SponsorOdense University Hospital

About this trial

Urinary tract infection (UTI) is one of the most common bacterial infections worldwide. It affects 150 million people annually. Treatment of patients with UTI entails a high consumption of antibiotics and large social and health costs. With this protocol, we want to elucidate alternative treatment methods for especially recurrent urinary tract infection. Bacteria have internal competitiveness (bacterial interference) and it is known that the non-pathogenic E.coli can outcompete the pathogenic E.coli in laboratory studies.

We intend to strengthen the clinical evidence that it can be used as patient treatment through a clinical, placebo-controlled, double-blind trial at Odense University Hospital.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Diagnosed with recurrent cystitis including 2 times of rUTI within the last 6 months or 3 times in the last 12 months, where at least 2 cultures show the same bacteria.

Normal investigation for lower urinary tract diseases (LUTD) including voiding diary, symptom scores, flexible cystoscopy, voiding diagram and test for residual urine.

Failed previously treatments.

Patients with native bladder with both spontaneous voiding, the need for clean intermittent catheter (CIC) or indwelling catheter.

Disqualifiers

Malignancy in the urinary tract, kidney-, ureteral- or bladder stones, age < 18 years, pregnancy, breastfeeding. Patients in ongoing orally antibiotic treatment. Not able to speak or understand Danish.

Trial design

Design model

Parallel

Treatments tested in this trial

  • ABU bladder lavage

    Biological/Vaccine

    Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with the non-pathogenic bacterial strain (ABU)

  • Saline bladder lavage

    Biological/Vaccine

    Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with saline

Treatment groups

80 Participants
are divided into 2 treatment groups
Group A: Patients prophylatic treated with ABUExperimental treatment 1 intervention
Group B: Patients control groupPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

The number of UTI events in the follow-up period

The number of prescriptions or hospital visits

Time frame
1½ year

Secondary outcomes

1

Time to first UTI after the intervention

Symptoms and the need for medical treatment or hospitalisation

Time frame
1½ year
2

Quality of life by standard Questionnaires_ICIQ-OABqol 08/04

International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life Module (ICIQ-OABqol). ICIQ-OABqol is a patient-completed questionnaire evaluating the quality of life (QoL) in patients with overactive bladder. It is translated into Danish and chosen because UTI symptoms often resemble OAB symptoms. Scoring: 25-160 overall score with greater values indicating increased impact on quality of life

Time frame
1½ year
3

O´Leary-Sant Voiding and Pain symptom score

The O'Leary-Sant Interstitial Cystitis Symptom Index is translated into Danish and chosen because UTI symptoms often resemble the bladder pain symptoms. The O'Leary-Sant instrument is comprised of a Symptom Index (score range: 0-20 points) and a Problem Index (score range: 0-16 points), each of which contains four questions related to urinary and pain symptoms. For each index, the score is calculated by summing the points for each item. Overall score with greater values indicating increased symptom severity.

Time frame
1½ year
4

EQ-5D-5L

Questionnaire evaluating quality of life at 5 terms (mobility, self-care, usual activities, pain, discomfort and anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. This results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. EQ-5D-5L health states may be converted into a single index value. The index values, presented in country-specific value sets, are a major feature of the EQ-5D instrument, facilitating the calculation of quality-adjusted life years (QALYs) that are used to inform economic evaluations of health care interventions.

Time frame
1½ year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.